Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease
Julien Chapuis(Inserm), Jean‐Charles Lambert(Inserm), Yves Lemoine(Institut Pasteur), Olivier Kerdraon(Inserm), Claudine Berr(Inserm), Ludovic Huot(Institut Pasteur), Philippe Amouyel(Inserm), Christine Hubans(Celescreen (France)), Luc Buée(Inserm), Fabienne Wavrant-DeVrièze(National Institutes of Health), Florence Pasquier(Centre Hospitalier Universitaire de Lille), Stéphanie Ferreira(Celescreen (France)), Christophe Tzourio(The University of Sydney), Faïza Bensemain(Inserm), Nathalie Fiévet(Inserm), David Hot(Institut Pasteur), David M. A. Mann(Salford Royal NHS Foundation Trust), Franck Hansmannel(Inserm), Takeshi Iwatsubo(National Center of Neurology and Psychiatry), Geoffroy Laumet(Michigan State University), M. Ilyas Kamboh(University of Pittsburgh), Steven T. DeKosky(University of Florida), C Lendon(QIMR Berghofer Medical Research Institute), Annick Alpérovitch(Inserm), J.F. Dartigues(Inserm), Anne‐Marie Ayral(Inserm), J J Hauw(Inserm), Claude‐Alain Maurage(Centre Hospitalier Universitaire de Lille)
Cited by 203
Related Papers
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Lecanemab in Early Alzheimer’s Disease
|New England Journal of Medicine|2022|5k
Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants
|The Lancet|2016|4.4k
New insights into the genetic etiology of Alzheimer’s disease and related dementias
|Nature Genetics|2022|2.5k